Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 5/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720019 | 0.93 | HSD11B1 (0.52) | MEN1KMT2AKDM4EBRD4ALDH1A1 | |
| SCHEMBL1719738 | 0.87 | AVPR1A (0.53) | MEN1KMT2AKDM4EBRD4ALDH1A1 | |
| SCHEMBL1720773 | 0.87 | HSD11B1 (0.51) | MEN1KMT2AKDM4EBRD4ALDH1A1 | |
| SCHEMBL16801703 | 0.86 | KDM4E (0.72) | MEN1KMT2AKDM4EBRD4ALDH1A1 | |
| SCHEMBL1720117 | 0.85 | RBP4 (0.54) | MEN1KMT2ANOS3NOS1HSD11B1 | |
| SCHEMBL1720201 | 0.81 | AVPR1A (0.48) | MEN1KMT2AL3MBTL3L3MBTL1HSD11B1 | |
| SCHEMBL1719708 | 0.81 | HSD11B1 (0.59) | MEN1KMT2AKDM4EALDH1A1L3MBTL3 | |
| SCHEMBL10229075 | 0.81 | HSD11B1 (0.45) | MEN1KMT2AKDM4EBRD4ALDH1A1 | |
| SCHEMBL1720025 | 0.78 | KDM4E (0.57) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL11010527 | 0.77 | DRD2 (0.56) | MEN1KMT2AKDM4EBRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | MEN1 3125/4885KMT2A 1063/4885KDM4E 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.